MYH9-related platelet disorders, Semin Thromb Hemost, vol.35, pp.189-203, 2009. ,
Gleichzeitige konstitutionelle Veranderungen an Neutrophilen und Thrombozyten, Helv Med Acta, vol.12, p.439, 1945. ,
The May-Hegglin anomaly: platelet function, ultrastructure and chromosome studies, Blood, vol.32, pp.950-961, 1968. ,
Hereditary macrothrombocytopathia, nephritis and deafness, Am J Med, vol.52, pp.299-310, 1972. ,
Fechtner syndrome-a variant of Alport's syndrome with leukocyte inclusions and macrothrombocytopenia, Blood, vol.65, pp.397-406, 1985. ,
Sebastian platelet syndrome: a new variant of hereditary macrothrombocytopenia with leukocyte inclusions, Blut, vol.61, pp.282-288, 1990. ,
Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium, Nat Genet, vol.26, pp.103-105, 2000. ,
Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes, Am J Hum Genet, vol.69, pp.1033-1045, 2001. ,
Mutation spectrum and genotype-phenotype correlations in a large French cohort of MYH9-Related Disorders, Mol Genet Genomic Med, vol.2, pp.297-312, 2014. ,
MYH9-related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations, Hum Mutat, vol.35, pp.236-247, 2014. ,
Position of nonmuscle myosin heavy chain IIA (NMMHC-IIA) mutations predicts the natural history of MYH9-related disease, Hum Mutat, vol.29, pp.409-417, 2008. ,
Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease, Kidney Int, vol.78, pp.207-214, 2010. ,
Renal manifestations of patients with MYH9-related disorders, Pediatr Nephrol Berl Ger, vol.26, pp.549-555, 2011. ,
Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/ Sebastian syndrome), Blood, vol.97, pp.1147-1149, 2001. ,
Myosin heavy chain-9-related disorders (MYH9-RD): a case report, Clin Kidney J, vol.6, pp.516-518, 2013. ,
Glomerular pathology in autosomal dominant MYH9 spectrum disorders: what are the clues telling us about disease mechanism?, Kidney Int, vol.78, pp.130-133, 2010. ,
Alport's syndrome associated with macrothrombopathic thrombocytopenia, Am J Clin Pathol, vol.72, pp.111-117, 1979. ,
Hereditary nephritis, platelet disorders and deafness-Epstein's syndrome, Pediatr Nephrol, vol.6, pp.38-43, 1992. ,
,
, Nihon Jinzo Gakkai Shi, vol.37, pp.62-68, 1995.
End-stage renal disease in two pediatric patients with Fechtner syndrome, Pediatr Nephrol, vol.13, pp.782-786, 1999. ,
Normal distribution of collagen IV in renal basement membranes in Epstein's syndrome, J Clin Pathol, vol.50, pp.919-922, 1997. ,
Genetics, clinical and pathological features of glomerulonephritis associated with mutations of nonmuscle myosin IIA (Fechtner syndrome) ,
, Am J Kidney Dis, vol.41, pp.95-104, 2003.
Epstein syndrome with rapid progression to end stage renal disease, Saudi J Kidney Dis Transplant, vol.20, pp.1076-1078, 2009. ,
Epstein syndrome presenting as renal failure in young patients, Ren Fail, vol.31, pp.582-585, 2009. ,
A large family with MYH9 disorder caused by E1841K mutation suffering from serious kidney and hearing impairment and cataracts, Ann Hematol, vol.91, pp.1147-1148, 2012. ,
Clinical, pathological, and genetic analysis of ten patients with MYH9-related disease, Acta Haematol, vol.129, pp.106-113, 2013. ,
Successful renal transplantation in MYH9-related disorder with severe macrothrombocytopenia: first report in Korea, Transplant Proc, vol.46, pp.654-656, 2014. ,
, Kidney Res Clin Pract, vol.34, pp.53-56, 2015.
COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis, Nephrol Dial Transplant, vol.31, pp.961-970, 2016. ,
Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene, Kidney Int, vol.65, pp.1598-1603, 2004. ,
MYH9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness, Medicine (Baltimore), vol.82, pp.203-215, 2003. ,
The May-Hegglin anomaly in a kidney transplant recipient, NDT Plus, vol.3, p.312, 2010. ,
Coincidental finding of May-Hegglin anomaly in a patient with end-stage renal failure, Am J Hematol, vol.40, pp.216-221, 1992. ,
Familial occurrence of the May-Hegglin anomaly: is the accompanying renal failure part of a new subentity, Ann Hematol, vol.80, pp.368-371, 2001. ,
,
renal dysfunction and nephrotic syndrome in a young male patient: a case report of MYH9-related disease, J Bras Nefrol, vol.40, pp.198-200, 2018. ,
Tubulointerstitial changes as a major determinant in the progression of renal damage, Am J Kidney Dis, vol.20, pp.1-17, 1992. ,
The prognostic value of histopathologic lesions in native kidney biopsy specimens: results from the Boston Kidney Biopsy Cohort Study, J Am Soc Nephrol, vol.29, pp.2213-2224, 2018. ,
Inherited thrombocytopenia: when a low platelet count does not mean ITP, Blood, vol.103, pp.390-398, 2004. ,
and platelets, too, Blood, vol.110, p.3093, 2007. ,
Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion, Blood, vol.110, pp.3183-3191, 2007. ,
Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations, Blood, vol.116, pp.5832-5837, 2010. ,
In vitro and in vivo effects of desmopressin on platelet function, Haematologica, vol.84, pp.891-896, 1999. ,
Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD, Blood, vol.119, pp.3333-3341, 2012. ,
Alteration of liver enzymes is a feature of the MYH9-related disease syndrome, PloS One, vol.7, p.35986, 2012. ,
Podocyte-specific deletion of Myh9 encoding nonmuscle myosin heavy chain 2A predisposes mice to glomerulopathy, Mol Cell Biol, vol.31, pp.2162-2170, 2011. ,
Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9 mutations in Epstein and Fechtner syndromes, J Am Soc Nephrol, vol.13, pp.65-74, 2002. ,
The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin, Blood, vol.107, pp.3564-3571, 2006. ,
Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A, Blood, vol.119, pp.238-250, 2012. ,